EFFECT OF DAPAGLIFLOZIN IN NON-ALCOHOLIC FATTY LIVER DISEASE
Article Sidebar
Main Article Content
Abstract
The development of non-alcoholic fatty liver disease (NAFLD), and hence insulin resistance, then type 2 diabetes mellitus in obese patients is of great importance in the choice of treatment tactics, duration, and possible ambiguous outcomes in the progression of NAFLD. Recent evidence suggests that sodium glucose cotransporter-2 (SGLT2) inhibitors inhibit the development of non-alcoholic steatohepatitis in humans, as well as improve liver steatosis in obese patients with type 2 diabetes.
Article Details
References
1. Cotter, T. G., & Rinella, M. (2020). Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology, 158(7), 1851–1864.https://doi.org/10.1053/j.gastro.2020.01.052
2. Mamasolievna, JN ANTIDIABETIC DRUGS IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW. Gospodarka i Innowacje., 2024, 48, 6-13.
3. Agababyan R. Irina, Djabbarova M. Nafisa. Current issues in modern treatment of nonalcoholic fatty liver disease//Journal of Biomedicine and Practice. 2024, vol.9, issue 2, pp.44-54
4. Agababyan I.R., Khokhlacheva D.S., Kim G.S., Khokhlacheva N.A. Study of the component composition of the body at an early stage of non-alcoholic fatty liver disease (in Russian). Recipe, 2024, Vol. 27, No. 1, 120-126.https://doi.org/10.34883/PI.2024.27.1.007
5. Targher, G., Tilg, H., & Byrne, C. D. (2021). Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. The lancet. Gastroenterology & hepatology, 6(7), 578–588. https://doi.org/10.1016/S2468-1253(21)00020-0
6. Ribeiro Dos Santos, L., & Baer Filho, R. (2020). Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. Metabolism open, 5, 100028. https://doi.org/10.1016/j.metop.2020.100028
7. Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017). Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Current therapeutic research, clinical and experimental, 87, 13–19. https://doi.org/10.1016/j.curtheres.2017.07.002
Aliyev, A. A. "A NEW FORM OF MODERN ECONOMY." Экономика и социум 4-1 (131) (2025): 65-68.
Aliyev, A. A. "THE ROLE OF INFORMATION TECHNOLOGY IN ECONOMIC GROWTH AND UNEMPLOYMENT MANAGEMENT." Экономика и социум 4-1 (131) (2025): 69-71.
Алиев, Азамжон, and Мухтасар Заирджон Кизи Мусаева. "Системы защиты биометрических данных." Academic research in educational sciences 2.4 (2021): 393-396.
8. Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018). Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia, 61(10), 2155–2163. https://doi.org/10.1007/s00125-018-4702-3
9. Eriksson, J. W., Lundkvist, P., Jansson, P. A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G. B., Risérus, U., Lind, L., & Oscarsson, J. (2018). Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia, 61(9), 1923–1934. https://doi.org/10.1007/s00125-018-4675-2
10. Das, C., Tripathy, D., Swain, S., Sudhakaran, N., Uthansingh, K., Mallick, P., & Pati, G. K. (2021). Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. Cureus, 13(5), e14974. https://doi.org/10.7759/cureus.14974